BCL11A and Schnyder corneal dystrophy: According to a recently published clinical study, two patients—one with transfusion-dependent β-thalassemia (TDT) and the other with SCD—received autologous CD34+ cells edited with CRISPR/Cas9 targeting the BCL11A enhancer.